Clinical trial
Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and…
NCT00171795 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171795 |
|---|---|
| Title | Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment |
| Official title | Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Traumatic Brain Injury |
| Intervention type | Drug |
| Interventions | Rivastigmine |
| Enrollment | 67 |
| Start date | Nov 1, 2002 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 23, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: